Factory Supply Posaconazole 99% Purity Pharmaceutical Posaconazole Powder Posaconazole

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung-Posaconazole
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Product Name: Posaconazole
• Name: Posaconazole Powder
• Appearance: White Powder
• Color: White Color
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anthelmintics
• Specific: COA
• Test Method: HPLC UV
• Shelf Life: 2 Years
• CAS No.: 171228-49-2
• Mf: C37h42f2n8o4
• Boiling Point: 850.7 C at 760 Mmhg
• Melting Point: 170-1720c
• Density: 1.36
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Xi′an Shaanxi
• Production Capacity: 5000kg/Month

Product Description

Factory Supply Posaconazole 99% Purity Pharmaceutical Posaconazole Powder Posaconazole

Product Description

Product Details

Product Name	Posaconazole
Appearance	White Powder
CAS No.	171228-49-2
MF	C37H42F2N8O4

Posaconazole is a triazole antifungal drug. It is used for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or those with hematologic malignancies with prolonged neutropenia from chemotherapy. It is also used for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to itraconazole and/or fluconazole therapy. It is also used to treat invasive infections by Candida, Mucor, and Aspergillus species in severely immunocompromised patients.

Application&Function

Posaconazole, launched in the UK, is the newest member of theazole class of antifungal agents to reach the market. It is indicated for the treatment and prophylaxis of a range of invasive fungal infections, including aspergillosis,fusariosis, chromoblastomycosis, mycetoma, and coccidiomycosis in patients who are refractory to, or intolerant of, standard therapy with amphotericin B and/or itraconazole. In the US, it is approved for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age who are at high risk of developing these infections due to being severely immunocompromised. Additionally, it is approved for the treatment of oropharyngeal candidiasis. Posaconazole has an expanded spectrum of activity over other members of the azole antifungals. In addition to potent activity against refractory cases of aspergillosis and fluconazole-resistant Candida, it demonstrates activity against Zygomycetes.

Specification